Delivery Order SPE2DB22D2206-SPE2DB25FJT99
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BOSULIF 400 mg tablets (30-count) with a ceiling value of $11,815.63. The contract, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order under a non-set-aside competitive procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- AmerisourceBergen Drug Corp was awarded a competitively bid delivery order valued at $23,631.26 for BOSULIF 400 mg tablets (30-count packages) by the Defense Logistics Agency Medical Supply Chain on August 20, 2025, with an ultimate completion date of September 11, 2025. The contract employs firm fixed-price pricing with no set-aside designation, and performance will be executed from the contractor's Conshohocken, Pennsylvania location. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of BOSULIF 400 mg tablets (30-count packages) with a ceiling value of $23,631.26. The contract is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $11,815.63 delivery order to AmerisourceBergen Drug Corp for BOSULIF 400 mg tablets (30-count units) on September 2, 2025, with an ultimate completion date of September 23, 2025. This firm fixed-price contract, utilizing no set-aside designation, represents a competitive award under the company's broader pharmaceutical supply agreements with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Bosulif 100 mg tablets (120-count units) with a ceiling value of $5,704.45. This firm fixed-price delivery order is scheduled for completion by August 22, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Bosulif 500 mg tablets (30-count units) under a firm fixed-price contract. The order carries a ceiling value of $11,301.40 and is scheduled for completion by September 25, 2025. This is a competitively awarded, non-set-aside delivery order with performance directed to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents...
- The Defense Logistics Agency awarded a delivery order valued at $70,893.78 to AmerisourceBergen Drug Corp for 30-tablet supplies of Bosulif 400 mg, a pharmaceutical product used in oncology treatment. This non-competitive, firm fixed-price delivery order was awarded on September 4, 2025, with a completion date of September 25, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child purchase order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,631.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Bosulif 400 mg tablets (30-count units). The contract, which has no set-aside designation, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,523.71 firm fixed-price delivery order is for the supply of BOSULIF 100 MG TABLET 120S, a pharmaceutical product. The contract has a period of performance through February 5, 2025 and does not include a set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $11,334.07 contract is for the supply of BOSULIF 400 MG TABLET 30S, a specialty medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJT99Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BOSULIF 100 mg tablets (120-count supply) on September 4, 2025, with a ceiling value of $17,113.35. This firm fixed-price contract represents a non-competitive set-aside delivery order with an ultimate completion date of September 25, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. BOSULIF is a prescription medication used in oncology treatment, reflecting the breadth of pharmaceutical products that AmerisourceBergen supplies through its federal contracts. This delivery order is a child contract issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal military and veteran healthcare systems, fulfilling medical supply needs across multiple therapeutic domains. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to deliver specialty medications, brand-name and generic drugs, vaccines, medical supplies, and specialized healthcare commodities to support Defense Health Agency operations and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.1k | 9/4/25 |